Tadeka
Takeda Pharmaceutical Co., Ltd
Pharmavitae Profile
| Publication Date | December 2007 |
| Publisher | Datamonitor |
| Product Type | Report |
| Pages | 157 |
| ISBN Number | not applicable |
| Product Code | DAT01188 |
Price
£1,990.00
approximately: $3,013 | €2,221
approximately: $3,013 | €2,221
print £2,010 ($3,043 | €2,243)
Order above formats by FAX
Summary
Introduction
This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Takeda's performance against key rivals in the ethical pharmaceutical sector
- Assess Takeda's reliance on four key blockbuster drugs: Actos, Prevacid, Blopress and Lupron
- See how this dependency on these four drugs will be exposed over the forecast period, as they all face some form of generic competition to 2012
Contents
- Introduction
- This Analysis Examines The Historical And Forecast Performance For Takeda In The Ethical Pharmaceutical Sector. The Profile Encompasses Global Company Strategy, Portfolio And Pipeline Analysis And Assessment Of Financial Performance, With 1-6 Year Sales Forecasts For Key Drugs. An Interactive Forecasting And Analysis Tool Provides Continually Updated Quantitative And Qualitative Information.
- Scope
- Highlights
- Reasons To Purchase
- Benchmark Takeda's Performance Against Key Rivals In The Ethical Pharmaceutical Sector Assess Takeda's Reliance On Four Key Blockbuster Drugs: Actos, Prevacid, Blopress And Lupron See How This Dependency On These Four Drugs Will Be Exposed Over The Forecast Period, As They All Face Some Form Of Generic Competition To 2012.
